[{"id":"9c9bdd8c-7abe-4b3e-b585-0d05ef9a65f5","acronym":"CodeBreak101","url":"https://clinicaltrials.gov/study/NCT04185883","created_at":"2021-01-18T20:24:19.309Z","updated_at":"2025-02-25T15:11:23.343Z","phase":"Phase 1","brief_title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","source_id_and_acronym":"NCT04185883 - CodeBreak101","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 04/29/2026","primary_completion_date":" 04/29/2026","study_txt":" Completion: 03/13/2028","study_completion_date":" 03/13/2028","last_update_posted":"2025-02-13"},{"id":"8411cc8f-a982-4f1c-a6ee-8d632174e0c9","acronym":"RMC-4630-02","url":"https://clinicaltrials.gov/study/NCT03989115","created_at":"2021-01-18T19:36:51.447Z","updated_at":"2024-07-02T16:35:44.769Z","phase":"Phase 1/2","brief_title":"Dose-Esc/Exp RMC4630 \u0026 Cobi in Relapsed/Refractory Solid Tumors \u0026 RMC4630\u0026 Osi in EGFR+ Locally Adv/Meta NSCLC","source_id_and_acronym":"NCT03989115 - RMC-4630-02","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" EGFR • KRAS • BRAF • NF1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NF1 mutation • BRAF amplification","tags":["EGFR • KRAS • BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NF1 mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cotellic (cobimetinib) • vociprotafib (RMC-4630)"],"overall_status":"Completed","enrollment":" Enrollment 113","initiation":"Initiation: 07/02/2019","start_date":" 07/02/2019","primary_txt":" Primary completion: 02/08/2022","primary_completion_date":" 02/08/2022","study_txt":" Completion: 02/08/2022","study_completion_date":" 02/08/2022","last_update_posted":"2023-06-26"},{"id":"0bc05807-8ef3-40d0-9ed4-10f0538739b7","acronym":"RMC-4630-03","url":"https://clinicaltrials.gov/study/NCT05054725","created_at":"2021-09-23T17:53:06.583Z","updated_at":"2024-07-02T16:35:51.630Z","phase":"Phase 2","brief_title":"Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies","source_id_and_acronym":"NCT05054725 - RMC-4630-03","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • vociprotafib (RMC-4630)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 12/30/2021","start_date":" 12/30/2021","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 03/03/2024","study_completion_date":" 03/03/2024","last_update_posted":"2023-04-03"},{"id":"a6bd584d-e831-4a8e-b3a3-6c9a3a80fc5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03634982","created_at":"2021-01-18T17:51:01.596Z","updated_at":"2024-07-02T16:36:04.616Z","phase":"Phase 1","brief_title":"Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors","source_id_and_acronym":"NCT03634982","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" KRAS • BRAF • NF1","pipe":" | ","alterations":" KRAS G12C • BRAF mutation • KRAS G12 • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • BRAF mutation • KRAS G12 • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vociprotafib (RMC-4630)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 09/28/2018","start_date":" 09/28/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-09-01"},{"id":"0b0004ce-6bfe-4d8e-982a-5d46b487e30e","acronym":"SHERPA","url":"https://clinicaltrials.gov/study/NCT04916236","created_at":"2021-06-07T15:53:34.728Z","updated_at":"2024-07-02T16:36:09.403Z","phase":"Phase 1","brief_title":"Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers","source_id_and_acronym":"NCT04916236 - SHERPA","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" EGFR • KRAS • PIK3CA • MET • PTEN • HRAS","pipe":"","alterations":" ","tags":["EGFR • KRAS • PIK3CA • MET • PTEN • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vociprotafib (RMC-4630) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-06-03"}]